Drugs / VRC-FLUDNA082-00-VP
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03186781 | Oct 2017 → Sep 2019 | influenza | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VRC-FLUDNA082-00-VP | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03186781 ↗ |
| Known as | DNA A/Sing | “The investigational DNA A/Sing vaccine, developed by the VRC, NIAID, is composed of a single closed-circular DNA plasmid that encodes the H2 protein of A/Singapore/1/57 influenza.” NCT03186781 ↗ |
| Modality | Vaccine | “VRC-FLUDNA082-00-VP (DNA A/Sing) is an investigational influenza plasmid DNA vaccine.” NCT03186781 ↗ |
| Route | Intramuscular | “Vaccines were administered intramuscularly (IM) in the deltoid muscle.” NCT03186781 ↗ |